{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:28:25Z","timestamp":1792783705426,"version":"4.5.0"},"reference-count":442,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Department of Health and Human Services","award":["HHSN272201100016I"],"award-info":[{"award-number":["HHSN272201100016I"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.antiviral.2018.09.003","type":"journal-article","created":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T23:07:32Z","timestamp":1537052852000},"page":"153-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"special_numbering":"C","title":["New therapies for human cytomegalovirus infections"],"prefix":"10.1016","volume":"159","author":[{"given":"William J.","family":"Britt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark N.","family":"Prichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.09.003_bib1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/cid\/cix222","article-title":"Cytomegalovirus urinary shedding in HIV-infected pregnant women and congenital cytomegalovirus infection","volume":"65","author":"Adachi","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002878","article-title":"The human cytomegalovirus assembly compartment: a masterpiece of viral manipulation of cellular processes that facilitates assembly and egress","volume":"8","author":"Alwine","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.09.003_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jpeds.2006.11.032","article-title":"Cranial ultrasound scanning and prediction of outcome in newborns with congenital cytomegalovirus infection","volume":"150","author":"Ancora","year":"2007","journal-title":"J. Pediatr."},{"key":"10.1016\/j.antiviral.2018.09.003_bib4","first-page":"132","article-title":"Novel inhibitors of human CMV","volume":"9","author":"Andrei","year":"2008","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.antiviral.2018.09.003_bib5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/187152609787847758","article-title":"Drug targets in cytomegalovirus infection","volume":"9","author":"Andrei","year":"2009","journal-title":"Infect. Disord. - Drug Targets"},{"key":"10.1016\/j.antiviral.2018.09.003_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/B978-0-12-405880-4.00004-4","article-title":"Advances in the treatment of varicella-zoster virus infections","volume":"67","author":"Andrei","year":"2013","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1086\/528718","article-title":"Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation","volume":"46","author":"Arthurs","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib8","doi-asserted-by":"crossref","first-page":"12345","DOI":"10.1128\/JVI.01175-09","article-title":"NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus protein UL142","volume":"83","author":"Ashiru","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib9","doi-asserted-by":"crossref","first-page":"7590","DOI":"10.1128\/JVI.01623-05","article-title":"Kinetics of influenza A virus infection in humans","volume":"80","author":"Baccam","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.virol.2004.03.015","article-title":"Phosphorylation of the RNA polymerase II carboxyl-terminal domain in human cytomegalovirus-infected cells and in vitro by the viral UL97 protein kinase","volume":"324","author":"Baek","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.09.003_bib11","doi-asserted-by":"crossref","first-page":"15989","DOI":"10.1038\/s41598-017-16262-z","article-title":"Long-read sequencing of human cytomegalovirus transcriptome reveals RNA isoforms carrying distinct coding potentials","volume":"7","author":"Balazs","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2018.09.003_bib12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jcv.2007.12.001","article-title":"Monitoring human cytomegalovirus infection in transplant recipients","volume":"41","author":"Baldanti","year":"2008","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib13","first-page":"703","article-title":"Congenital cytomegalovirus infection of the brain: imaging analysis and embryologic considerations","volume":"15","author":"Barkovich","year":"1994","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib14","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/MOT.0b013e32833bd3b5","article-title":"Revisiting the effects of CMV on long-term transplant outcome","volume":"15","author":"Baron","year":"2010","journal-title":"Curr. Opin. Organ Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib15","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1128\/AAC.46.8.2381-2386.2002","article-title":"Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro","volume":"46","author":"Beadle","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ctr.12686","article-title":"Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis","volume":"30","author":"Beam","year":"2016","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1086\/421912","article-title":"Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection","volume":"190","author":"Bidanset","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib18","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1128\/JVI.00986-15","article-title":"Antagonistic relationship between human cytomegalovirus pUL27 and pUL97 activities during infection","volume":"89","author":"Bigley","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coviro.2016.01.013","article-title":"HSV antivirals - current and future treatment options","volume":"18","author":"Birkmann","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib20","series-title":"Maribavir: a Promising New Antiherpes Therapeutic Agent","author":"Biron","year":"2006"},{"key":"10.1016\/j.antiviral.2018.09.003_bib21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2006.05.002","article-title":"Antiviral drugs for cytomegalovirus diseases","volume":"71","author":"Biron","year":"2006","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1128\/AAC.18.3.443","article-title":"In vitro susceptibility of varicella-zoster virus to acyclovir","volume":"18","author":"Biron","year":"1980","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib23","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","article-title":"Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action","volume":"46","author":"Biron","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib24","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1073\/pnas.82.8.2473","article-title":"Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus","volume":"82","author":"Biron","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.09.003_bib25","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1128\/AAC.02641-14","article-title":"Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection model","volume":"58","author":"Biswas","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1399-3062.2011.00705.x","article-title":"Risk factors and clinical outcomes of cytomegalovirus disease occurring more than one year post solid organ transplantation","volume":"14","author":"Blyth","year":"2012","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib27","first-page":"1093","article-title":"Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients","volume":"18","author":"Bodro","year":"2012","journal-title":"Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc."},{"key":"10.1016\/j.antiviral.2018.09.003_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-2729","article-title":"Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial","volume":"162","author":"Boeckh","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1083-8791(03)00287-8","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies","volume":"9","author":"Boeckh","year":"2003","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/rmv.344","article-title":"Human cytomegalovirus terminase as a target for antiviral chemotherapy","volume":"12","author":"Bogner","year":"2002","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1006\/viro.1993.1477","article-title":"Identification of the gene product encoded by ORF UL56 of the human cytomegalovirus genome","volume":"196","author":"Bogner","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.09.003_bib32","series-title":"Cytomegaloviruses: from Molecular Pathogenesis to Intervention","first-page":"1","article-title":"Synopsis of clinical aspects of human cytomegalovirus disease","author":"Boppana","year":"2013"},{"key":"10.1016\/j.antiviral.2018.09.003_bib33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/978-1-62703-788-4_17","article-title":"Recent approaches and strategies in the generation of antihuman cytomegalovirus vaccines","volume":"1119","author":"Boppana","year":"2014","journal-title":"Meth. Mol. Biol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib34","first-page":"158A","article-title":"Newborn findings and outcome in children with symptomatic congenital CMV infection","volume":"31","author":"Boppana","year":"1992","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00006454-199202000-00007","article-title":"Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality","volume":"11","author":"Boppana","year":"1992","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.antiviral.2018.09.003_bib36","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1056\/NEJM200105033441804","article-title":"Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity","volume":"344","author":"Boppana","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib37","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa1006561","article-title":"Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns","volume":"364","author":"Boppana","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib38","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/j.transproceed.2014.09.058","article-title":"Chronic allograft dysfunction in kidney transplant recipients: long-term single-center study","volume":"46","author":"Boratynska","year":"2014","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.antiviral.2018.09.003_bib39","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1084\/jem.187.5.813","article-title":"Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94\/NKG2 confers protection from natural killer cell-mediated lysis","volume":"187","author":"Borrego","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib40","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1128\/JVI.00384-16","article-title":"The essential human cytomegalovirus proteins pUL77 and pUL93 are structural components necessary for viral genome encapsidation","volume":"90","author":"Borst","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib41","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1128\/JVI.01955-12","article-title":"The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89","volume":"87","author":"Borst","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib42","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1128\/JVI.01967-07","article-title":"The essential human cytomegalovirus gene UL52 is required for cleavage-packaging of the viral genome","volume":"82","author":"Borst","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib43","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1111\/j.1600-6143.2011.03618.x","article-title":"Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients","volume":"11","author":"Bosch","year":"2011","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib44","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1399-3062.2011.00624.x","article-title":"Risk factors for late-onset cytomegalovirus disease in donor seropositive\/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis","volume":"13","author":"Boudreault","year":"2011","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib45","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35869","article-title":"HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C","volume":"391","author":"Braud","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.09.003_bib46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/AAC.00971-10","article-title":"Oral hexadecyloxypropyl-cidofovir therapy in pregnant Guinea pigs improves outcome in the congenital model of cytomegalovirus infection","volume":"55","author":"Bravo","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib47","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0166-3542(01)00208-X","article-title":"Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses","volume":"54","author":"Brideau","year":"2002","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib49","series-title":"Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis","article-title":"Maturation and egress","author":"Britt","year":"2007"},{"key":"10.1016\/j.antiviral.2018.09.003_bib50","series-title":"Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis","first-page":"311","article-title":"Maturation and egress","author":"Britt","year":"2007"},{"key":"10.1016\/j.antiviral.2018.09.003_bib51","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0042-6822(84)90193-4","article-title":"Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus","volume":"135","author":"Britt","year":"1984","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.09.003_bib52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0168-1702(85)90018-8","article-title":"Identification of a 65 000 dalton virion envelope protein of human cytomegalovirus","volume":"4","author":"Britt","year":"1985","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib53","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1399-0012.2010.01208.x","article-title":"The impact of cytomegalovirus infection >\/=1 year after primary renal transplantation","volume":"24","author":"Browne","year":"2010","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/v9090249","article-title":"Die another day: inhibition of cell death pathways by cytomegalovirus","volume":"9","author":"Brune","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2018.09.003_bib55","doi-asserted-by":"crossref","first-page":"9077","DOI":"10.1128\/JVI.75.19.9077-9086.2001","article-title":"A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products","volume":"75","author":"Buerger","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib56","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00430-015-0397-y","article-title":"The proteome of human cytomegalovirus virions and dense bodies is conserved across different strains","volume":"204","author":"Buscher","year":"2015","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003825","article-title":"Cyclin A degradation by primate cytomegalovirus protein pUL21a counters its innate restriction of virus replication","volume":"9","author":"Caffarelli","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.09.003_bib58","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.braindev.2013.04.001","article-title":"Role of cerebral ultrasound and magnetic resonance imaging in newborns with congenital cytomegalovirus infection","volume":"36","author":"Capretti","year":"2014","journal-title":"Brain Dev."},{"key":"10.1016\/j.antiviral.2018.09.003_bib59","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.transproceed.2007.07.039","article-title":"Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients","volume":"39","author":"Cervera","year":"2007","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.antiviral.2018.09.003_bib60","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.1038\/s41598-017-08866-2","article-title":"Human cytomegalovirus escapes immune recognition by NK cells through the downregulation of B7-H6 by the viral genes US18 and US20","volume":"7","author":"Charpak-Amikam","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2018.09.003_bib61","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib62","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1021\/jm0205245","article-title":"Structure-activity relationships of (S,Z)-2-aminopurine methylenecyclopropane analogues of nucleosides. Variation of purine-6 substituents and activity against herpesviruses and hepatitis B virus","volume":"46","author":"Chen","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.09.003_bib63","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1710522114","article-title":"Transcriptome-wide characterization of human cytomegalovirus in natural infection and experimental latency","volume":"114","author":"Cheng","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.antiviral.2018.09.003_bib64","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01040-17","article-title":"Monitoring of cytomegalovirus (CMV)-specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical utility of the QuantiFERON-CMV assay for management of posttransplant CMV infection","volume":"56","author":"Chiereghin","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib65","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01857-16","article-title":"Identification of a continuous neutralizing epitope within UL128 of human cytomegalovirus","volume":"91","author":"Chiuppesi","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib66","doi-asserted-by":"crossref","first-page":"11884","DOI":"10.1128\/JVI.01701-15","article-title":"Vaccine-derived neutralizing antibodies to the human cytomegalovirus gH\/gL pentamer potently block primary cytotrophoblast infection","volume":"89","author":"Chiuppesi","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib67","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41467-017-02624-8","article-title":"Human cytomegalovirus-encoded US9 targets MAVS and STING signaling to evade type I interferon immune responses","volume":"9","author":"Choi","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2018.09.003_bib68","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jac\/dkq198","article-title":"ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2","volume":"65","author":"Chono","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib69","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bcp.2012.05.020","article-title":"Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir)","volume":"84","author":"Chono","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib70","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJM198605293142205","article-title":"Acquisition of donor strains of cytomegalovirus by renal-transplant recipients","volume":"314","author":"Chou","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib71","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/rmv.574","article-title":"Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir","volume":"18","author":"Chou","year":"2008","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib72","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.00186-10","article-title":"Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance","volume":"54","author":"Chou","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib73","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/QCO.0000000000000170","article-title":"Approach to drug-resistant cytomegalovirus in transplant recipients","volume":"28","author":"Chou","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib74","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.antiviral.2018.09.003_bib75","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01325-17","article-title":"Comparison of cytomegalovirus terminase gene mutations selected after exposure to three distinct inhibitor compounds","volume":"61","author":"Chou","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.10.019","article-title":"A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","volume":"148","author":"Chou","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib77","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1128\/AAC.00214-16","article-title":"Novel cytomegalovirus UL54 DNA polymerase gene mutations selected in vitro that confer brincidofovir resistance","volume":"60","author":"Chou","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib78","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1128\/AAC.00511-13","article-title":"Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance","volume":"57","author":"Chou","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib79","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1128\/AAC.02544-13","article-title":"Cytomegalovirus mutants resistant to ganciclovir and cidofovir differ in susceptibilities to synguanol and its 6-ether and 6-thioether derivatives","volume":"58","author":"Chou","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib80","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1086\/515648","article-title":"Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy","volume":"178","author":"Chou","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib81","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1128\/AAC.00577-06","article-title":"Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus","volume":"50","author":"Chou","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib82","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1128\/JVI.78.13.7124-7130.2004","article-title":"Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir","volume":"78","author":"Chou","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib83","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1086\/338362","article-title":"Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir","volume":"185","author":"Chou","year":"2002","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib84","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1086\/518514","article-title":"Cytomegalovirus UL97 kinase mutations that confer maribavir resistance","volume":"196","author":"Chou","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib85","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0166-3542(03)00110-4","article-title":"Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney","volume":"59","author":"Ciesla","year":"2003","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib86","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0026-895X(25)09608-7","article-title":"Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells","volume":"50","author":"Cihlar","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib87","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1128\/JVI.00058-07","article-title":"Human cytomegalovirus UL84 interacts with an RNA stem-loop sequence found within the RNA\/DNA hybrid region of oriLyt","volume":"81","author":"Colletti","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib88","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s40588-017-0072-8","article-title":"The loss of binary: pushing the herpesvirus latency paradigm","volume":"4","author":"Collins-McMillen","year":"2017","journal-title":"Curr. Clin. Microbiol. Rep."},{"key":"10.1016\/j.antiviral.2018.09.003_bib89","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/tid.12365","article-title":"Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis","volume":"17","author":"Crocchiolo","year":"2015","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib90","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/0002-9343(92)90329-A","article-title":"Mechanism of action of foscarnet against viral polymerases","volume":"92","author":"Crumpacker","year":"1992","journal-title":"Am. J. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib91","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1055\/s-0042-1748054","article-title":"Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus","volume":"11","author":"Dahle","year":"2000","journal-title":"J. Am. Acad. Audiol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003525","article-title":"The smallest capsid protein mediates binding of the essential tegument protein pp150 to stabilize DNA-containing capsids in human cytomegalovirus","volume":"9","author":"Dai","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.09.003_bib93","doi-asserted-by":"crossref","first-page":"11861","DOI":"10.1128\/JVI.01077-07","article-title":"Three-dimensional structure of the human cytomegalovirus cytoplasmic virion assembly complex includes a reoriented secretory apparatus","volume":"81","author":"Das","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib94","series-title":"Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis","article-title":"Comparative analysis of the genomes","author":"Davison","year":"2007"},{"key":"10.1016\/j.antiviral.2018.09.003_bib95","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1099\/vir.0.18606-0","article-title":"The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome.[erratum appears in J Gen Virol. 2003 Apr;84(Pt 4):1053]","volume":"84","author":"Davison","year":"2003","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib96","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3851\/IMP2533","article-title":"Selective anti-herpesvirus agents","volume":"23","author":"De Clercq","year":"2013","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib97","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1081\/NCN-200059772","article-title":"Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines","volume":"24","author":"De Clercq","year":"2005","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.09.003_bib98","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic nucleoside phosphonates: a key class of antiviral drugs","volume":"4","author":"De Clercq","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2018.09.003_bib99","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/323464a0","article-title":"A novel selective broad-spectrum anti-DNA virus agent","volume":"323","author":"De Clercq","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.09.003_bib100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1076\/ocii.7.3.189.4007","article-title":"Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis","volume":"7","author":"de Smet","year":"1999","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.antiviral.2018.09.003_bib101","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-2004-815833","article-title":"The spectrum of cranial ultrasound and magnetic resonance imaging abnormalities in congenital cytomegalovirus infection","volume":"35","author":"de Vries","year":"2004","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.antiviral.2018.09.003_bib102","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.healun.2015.03.015","article-title":"Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation","volume":"34","author":"Delgado","year":"2015","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib103","doi-asserted-by":"crossref","first-page":"12221","DOI":"10.1128\/JVI.02382-15","article-title":"Human cytomegalovirus pUL93 is required for viral genome cleavage and packaging","volume":"89","author":"DeRussy","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib104","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/00007890-200103270-00013","article-title":"Cytomegalovirus infection and graft rejection in renal transplantation","volume":"71","author":"Dickenmann","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2018.09.003_bib105","doi-asserted-by":"crossref","first-page":"14660","DOI":"10.1128\/JVI.79.23.14660-14667.2005","article-title":"Interaction of the putative human cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides","volume":"79","author":"Dittmer","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib106","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/rmv.544","article-title":"New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection","volume":"17","author":"Dollard","year":"2007","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib107","series-title":"Benzimidazoled-ribonucleosides as Antiviral Agents that Target HCMV Terminase","author":"Drach","year":"2006"},{"issue":"4","key":"10.1016\/j.antiviral.2018.09.003_bib108","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jpeds.2013.12.007","article-title":"Spectrum of disease and outcome in children with symptomatic congenital cytomegalovirus infection","volume":"164","author":"Dreher","year":"2014","journal-title":"J. Pediatr."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2018.09.003_bib109","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/510206","article-title":"Recommendations for the management of herpes zoster","volume":"44","author":"Dworkin","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib110","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/cid\/cis818","article-title":"State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician","volume":"55","author":"Egli","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib111","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1073\/pnas.74.12.5716","article-title":"Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine","volume":"74","author":"Elion","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.09.003_bib112","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jcv.2012.02.020","article-title":"Importance of the cytomegalovirus seropositive recipient as a contributor to disease burden after solid organ transplantation","volume":"54","author":"Emery","year":"2012","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib113","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jcv.2011.07.005","article-title":"Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age","volume":"52","author":"Enders","year":"2011","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib114","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/civ215","article-title":"Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices","volume":"61","author":"Erard","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib115","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/ndt\/gfr306","article-title":"Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies","volume":"27","author":"Erdbruegger","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib116","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0166-3542(02)00094-3","article-title":"Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus","volume":"56","author":"Evers","year":"2002","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib117","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00003495-199039040-00008","article-title":"Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections","volume":"39","author":"Faulds","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2018.09.003_bib118","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.transproceed.2017.07.001","article-title":"Enzyme-linked immunospot assay as a complementary method to assess and monitor cytomegalovirus infection in kidney transplant recipients on pre-emptive antiviral therapy: a single-center experience","volume":"49","author":"Favi","year":"2017","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.antiviral.2018.09.003_bib119","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ajcp\/22.5.424","article-title":"A new laboratory aid in the clinical diagnosis of inclusion disease of infancy","volume":"22","author":"Fetterman","year":"1952","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib120","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.antiviral.2013.08.024","article-title":"Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivir","volume":"100","author":"Field","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib121","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004058","article-title":"Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation","volume":"10","author":"Fielding","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.09.003_bib122","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.22206","article-title":"Control of immune ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell activation","volume":"6","author":"Fielding","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.antiviral.2018.09.003_bib123","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/cid\/cix259","article-title":"Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients","volume":"65","author":"Fisher","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib124","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jmv.21727","article-title":"Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital","volume":"82","author":"Fleming","year":"2010","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib125","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.3390\/v4101928","article-title":"Prevention of cellular suicide by cytomegaloviruses","volume":"4","author":"Fliss","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2018.09.003_bib126","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/cid\/cit945","article-title":"A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant","volume":"58","author":"Florescu","year":"2014","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl. 4","key":"10.1016\/j.antiviral.2018.09.003_bib127","doi-asserted-by":"crossref","first-page":"S182","DOI":"10.1093\/cid\/cit609","article-title":"Congenital cytomegalovirus infection: audiologic outcome","volume":"57","author":"Fowler","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib128","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0022-3476(97)70248-8","article-title":"Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection","volume":"130","author":"Fowler","year":"1997","journal-title":"J. Pediatr."},{"key":"10.1016\/j.antiviral.2018.09.003_bib129","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1600-6143.2009.02824.x","article-title":"The 'indirect' effects of cytomegalovirus infection","volume":"9","author":"Freeman","year":"2009","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib130","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.chom.2017.01.001","article-title":"Human cytomegalovirus tegument protein UL82 inhibits STING-mediated signaling to evade antiviral immunity","volume":"21","author":"Fu","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2018.09.003_bib131","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(97)05535-9","article-title":"Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients","volume":"350","author":"Gane","year":"1997","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.antiviral.2018.09.003_bib132","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/ajt.12298","article-title":"CMV infection in the donor and increased kidney graft loss: impact of full HLA-I mismatch and posttransplantation CD8(+) cell reduction","volume":"13","author":"Gatault","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib133","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2165\/00003088-200241040-00002","article-title":"Fomivirsen: clinical pharmacology and potential drug interactions","volume":"41","author":"Geary","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.antiviral.2018.09.003_bib134","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1128\/AAC.02311-13","article-title":"Metabolism of cyclopropavir and ganciclovir in human cytomegalovirus-infected cells","volume":"58","author":"Gentry","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib135","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bcp.2010.09.005","article-title":"Phosphorylation of antiviral and endogenous nucleotides to di- and triphosphates by guanosine monophosphate kinase","volume":"81","author":"Gentry","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib136","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1128\/AAC.00468-10","article-title":"Stereoselective phosphorylation of cyclopropavir by pUL97 and competitive inhibition by maribavir","volume":"54","author":"Gentry","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib137","series-title":"Cytomegaloviruses: from Molecular Pathogenesis to Intervention","first-page":"230","article-title":"Morphogenesis of the cytomegalovirus virion and subviral particles","author":"Gibson","year":"2013"},{"key":"10.1016\/j.antiviral.2018.09.003_bib138","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1099\/0022-1317-81-9-2231","article-title":"The potential terminase subunit of human cytomegalovirus, pUL56, is translocated into the nucleus by its own nuclear localization signal and interacts with importin alpha","volume":"81","author":"Giesen","year":"2000","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib139","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0014-5793(00)01407-1","article-title":"Targeting of the gene product encoded by ORF UL56 of human cytomegalovirus into viral replication centers","volume":"471","author":"Giesen","year":"2000","journal-title":"FEBS Lett."},{"key":"10.1016\/j.antiviral.2018.09.003_bib140","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1128\/AAC.01794-13","article-title":"Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure","volume":"58","author":"Goldner","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib141","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anti-cytomegalovirus compound AIC246 inhibits HCMV replication through a specific antiviral mechanism that involves the viral terminase","author":"Goldner","year":"2011","journal-title":"J. Virol."},{"issue":"20","key":"10.1016\/j.antiviral.2018.09.003_bib142","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85(20)","author":"Goldner","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib143","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.tim.2015.08.007","article-title":"Stealing the keys to the kitchen: viral manipulation of the host cell metabolic network","volume":"23","author":"Goodwin","year":"2015","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib144","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2010-03-273508","article-title":"Immune monitoring with iT Ag MHC tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study","volume":"116","author":"Gratama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2018.09.003_bib145","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.bbmt.2012.05.015","article-title":"Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation","volume":"18","author":"Green","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib146","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib147","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/QCO.0000000000000107","article-title":"Cytomegalovirus","volume":"27","author":"Griffiths","year":"2014","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib148","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(88)90685-X","article-title":"Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus","volume":"2","author":"Grundy","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2018.09.003_bib149","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbmt.2011.05.010","article-title":"Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation","volume":"18","author":"Guerrero","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib150","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00430-015-0410-5","article-title":"Manipulation of apoptosis and necroptosis signaling by herpesviruses","volume":"204","author":"Guo","year":"2015","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib151","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12732","article-title":"Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting","volume":"19","author":"Hakimi","year":"2017","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib152","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bbmt.2013.10.019","article-title":"HCMV infection of humanized mice after transplantation of G-CSF-mobilized peripheral blood stem cells from HCMV-seropositive donors","volume":"20","author":"Hakki","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib153","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1128\/JVI.01923-10","article-title":"Human cytomegalovirus disrupts the major histocompatibility complex class I peptide-loading complex and inhibits tapasin gene transcription","volume":"85","author":"Halenius","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib154","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000275","article-title":"Viral mimicry of Cdc2\/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress","volume":"5","author":"Hamirally","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.09.003_bib155","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"Alemtuzumab induction in renal transplantation","volume":"364","author":"Hanaway","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib156","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00109-17","article-title":"Human cytomegalovirus MicroRNAs mir-US5-1 and mir-UL112-3p block proinflammatory cytokine production in response to NF-kappaB-Activating factors through direct downregulation of IKKalpha and IKKbeta","volume":"8","author":"Hancock","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2018.09.003_bib157","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1126\/science.1185350","article-title":"Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus","volume":"328","author":"Hansen","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2018.09.003_bib158","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJM197608262950902","article-title":"School failure and deafness after \u201csilent\u201d congenital cytomegalovirus infection","volume":"295","author":"Hanshaw","year":"1976","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib159","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/tri.12043","article-title":"Selection of induction therapy in kidney transplantation","volume":"26","author":"Hardinger","year":"2013","journal-title":"Transpl. Int."},{"key":"10.1016\/j.antiviral.2018.09.003_bib160","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1086\/426831","article-title":"Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro","volume":"191","author":"Hartline","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib161","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2004.10.003","article-title":"Inhibition of herpesvirus replication by a series of 4-oxo-dihydroquinolines with viral polymerase activity","volume":"65","author":"Hartline","year":"2005","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib162","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/088307389100600203","article-title":"Lissencephaly-pachygyria associated with congenital cytomegalovirus infection","volume":"6","author":"Hayward","year":"1991","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib163","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1128\/jvi.71.1.405-411.1997","article-title":"The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines","volume":"71","author":"He","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib164","doi-asserted-by":"crossref","first-page":"10929","DOI":"10.1128\/JVI.76.21.10929-10941.2002","article-title":"Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation","volume":"76","author":"Hegde","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib165","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1432-2277.2006.00364.x","article-title":"Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival","volume":"19","author":"Helantera","year":"2006","journal-title":"Transpl. Int."},{"key":"10.1016\/j.antiviral.2018.09.003_bib166","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1097\/01.TP.0000064709.20841.E1","article-title":"The impact of cytomegalovirus infections and acute rejection episodes on the development of vascular changes in 6-month protocol biopsy specimens of cadaveric kidney allograft recipients","volume":"75","author":"Helantera","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2018.09.003_bib167","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/tid.12247","article-title":"Current characteristics and outcome of cytomegalovirus infections after kidney transplantation","volume":"16","author":"Helantera","year":"2014","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib168","series-title":"Recent Developments in Anti-herpesviral Therapy Based on Protein Kinase Inhibitors","author":"Herget","year":"2006"},{"key":"10.1016\/j.antiviral.2018.09.003_bib169","article-title":"Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients","volume":"1","author":"Hill","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.antiviral.2018.09.003_bib170","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/095632029600700301","article-title":"Cidofovir, a new agent with potent anti-herpesvirus activity","volume":"7","author":"Hitchcock","year":"1996","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib171","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003774.pub4","article-title":"Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients","author":"Hodson","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.antiviral.2018.09.003_bib172","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.coviro.2014.03.015","article-title":"Cytomegalovirus microRNAs","volume":"7","author":"Hook","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib173","doi-asserted-by":"crossref","first-page":"A84","DOI":"10.1016\/j.antiviral.2009.01.005","article-title":"Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art","volume":"82","author":"Hostetler","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib174","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0006-2952(97)82446-X","article-title":"Enhanced oral absorption and antiviral activity of 1-O-octadecyl-sn-glycero-3-phospho-acyclovir and related compounds in hepatitis B virus infection, in vitro","volume":"53","author":"Hostetler","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib175","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/095632020101200104","article-title":"In vitro and in vivo activity of 1-O-hexadecylpropanediol-3-phospho-ganciclovir and 1-O-hexadecylpropanediol-3-phospho-penciclovir in cytomegalovirus and herpes simplex virus infections","volume":"12","author":"Hostetler","year":"2001","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib176","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.1152095","article-title":"Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function","volume":"320","author":"Hume","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2018.09.003_bib177","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1161\/CIRCULATIONAHA.106.627570","article-title":"Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children","volume":"115","author":"Hussain","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.antiviral.2018.09.003_bib178","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.antiviral.2016.08.005","article-title":"The chemical class of quinazoline compounds provides a core structure for the design of anticytomegaloviral kinase inhibitors","volume":"134","author":"Hutterer","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib179","doi-asserted-by":"crossref","first-page":"6943","DOI":"10.1074\/jbc.M108984200","article-title":"ATPase activity of the terminase subunit pUL56 of human cytomegalovirus","volume":"277","author":"Hwang","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.09.003_bib180","doi-asserted-by":"crossref","first-page":"6583","DOI":"10.1074\/jbc.M116.773150","article-title":"Human cytomegalovirus-encoded viral cyclin-dependent kinase (v-CDK) UL97 phosphorylates and inactivates the retinoblastoma protein-related p107 and p130 proteins","volume":"292","author":"Iwahori","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.09.003_bib181","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000096156","article-title":"Audiological outcome of infants with congenital cytomegalovirus infection in a prospective study","volume":"12","author":"Iwasaki","year":"2007","journal-title":"Audiol. Neuro. Otol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib182","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1128\/AAC.42.9.2240","article-title":"Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group","volume":"42","author":"Jabs","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib183","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1089\/aid.1994.10.917","article-title":"Current management of cytomegalovirus disease in patients with AIDS","volume":"10","author":"Jacobson","year":"1994","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.antiviral.2018.09.003_bib184","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJM199707103370207","article-title":"Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome","volume":"337","author":"Jacobson","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib185","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1128\/AAC.00571-11","article-title":"Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase","volume":"55","author":"James","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib186","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/cpt.3","article-title":"Helicase-primase as a target of new therapies for herpes simplex virus infections","volume":"97","author":"James","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2018.09.003_bib187","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1128\/AAC.00062-13","article-title":"Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus","volume":"57","author":"James","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib188","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2174\/187152611797636668","article-title":"The genetic basis of human cytomegalovirus resistance and current trends in antiviral resistance analysis","volume":"11","author":"James","year":"2011","journal-title":"Infect. Disord. - Drug Targets"},{"key":"10.1016\/j.antiviral.2018.09.003_bib189","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1128\/JVI.00060-06","article-title":"Human cytomegalovirus attenuates interleukin-1beta and tumor necrosis factor alpha proinflammatory signaling by inhibition of NF-kappaB activation","volume":"80","author":"Jarvis","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib190","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1186\/s12879-015-1321-1","article-title":"Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients","volume":"15","author":"Johansson","year":"2015","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib191","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/00365540903341828","article-title":"Cytomegalovirus and long-term outcome after lung transplantation in Gothenburg, Sweden","volume":"42","author":"Johanssson","year":"2010","journal-title":"Scand. J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib192","first-page":"101","article-title":"Inhibition of the MHC class II antigen presentation pathway by human cytomegalovirus","volume":"269","author":"Johnson","year":"2002","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib193","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1177\/00912709922008452","article-title":"Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects","volume":"39","author":"Jung","year":"1999","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib194","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1128\/MMBR.00040-07","article-title":"Tegument proteins of human cytomegalovirus","volume":"72","author":"Kalejta","year":"2008","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.antiviral.2018.09.003_bib195","doi-asserted-by":"crossref","first-page":"870","DOI":"10.7326\/0003-4819-143-12-200512200-00005","article-title":"Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients","volume":"143","author":"Kalil","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib196","doi-asserted-by":"crossref","first-page":"10659","DOI":"10.1128\/JVI.00497-07","article-title":"Human cytomegalovirus protein kinase UL97 forms a complex with the tegument phosphoprotein pp65","volume":"81","author":"Kamil","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib197","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1111\/ajt.13781","article-title":"Easier control of late-onset cytomegalovirus disease following universal prophylaxis through an early antiviral immune response in donor-positive, recipient-negative kidney transplants","volume":"16","author":"Kaminski","year":"2016","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib198","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/JVI.77.4.2359-2368.2003","article-title":"Conserved protein kinases encoded by herpesviruses and cellular protein kinase cdc2 target the same phosphorylation site in eukaryotic elongation factor 1delta","volume":"77","author":"Kawaguchi","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib199","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/1346-8138.13948","article-title":"Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: a randomized, double-blind, valaciclovir-controlled phase 3 study","volume":"44","author":"Kawashima","year":"2017","journal-title":"J. Dermatol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib200","first-page":"66","article-title":"Cytomegalovirus retinitis in the era of highly active antiretroviral therapy","volume":"14","author":"Kedhar","year":"2007","journal-title":"Herpes J. IHMF"},{"key":"10.1016\/j.antiviral.2018.09.003_bib201","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1128\/AAC.48.5.1869-1871.2004","article-title":"Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro","volume":"48","author":"Keith","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib202","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection","volume":"17","author":"Kenneson","year":"2007","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib203","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1128\/AAC.48.12.4745-4753.2004","article-title":"Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections","volume":"48","author":"Kern","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib204","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1128\/AAC.48.9.3516-3522.2004","article-title":"Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir","volume":"48","author":"Kern","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib205","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1128\/AAC.48.5.1749-1755.2004","article-title":"Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections","volume":"48","author":"Kern","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib206","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1128\/AAC.49.3.1039-1045.2005","article-title":"In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication","volume":"49","author":"Kern","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib207","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.transproceed.2011.12.063","article-title":"Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study","volume":"44","author":"Kim","year":"2012","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.antiviral.2018.09.003_bib208","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1086\/528376","article-title":"Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease","volume":"197","author":"Kimberlin","year":"2008","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib209","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1404599","article-title":"Valganciclovir for symptomatic congenital cytomegalovirus disease","volume":"372","author":"Kimberlin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib210","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-3476(03)00192-6","article-title":"Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial","volume":"143","author":"Kimberlin","year":"2003","journal-title":"J. Pediatr."},{"key":"10.1016\/j.antiviral.2018.09.003_bib211","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.antiviral.2015.04.001","article-title":"TAOK3 phosphorylates the methylenecyclopropane nucleoside MBX 2168 to its monophosphate","volume":"119","author":"Komazin-Meredith","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib212","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1128\/AAC.00978-13","article-title":"Human herpesvirus 6 U69 kinase phosphorylates the methylenecyclopropane nucleosides cyclopropavir, MBX 2168, and MBX 1616 to their monophosphates","volume":"57","author":"Komazin-Meredith","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib213","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1128\/JVI.78.2.710-715.2004","article-title":"Role of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribonucleosides","volume":"78","author":"Komazin","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib214","doi-asserted-by":"crossref","first-page":"235","DOI":"10.12659\/AOT.896938","article-title":"Pulmonary cytomegalovirus replication in renal transplant patients with late onset pneumonitis","volume":"21","author":"Konigshausen","year":"2016","journal-title":"Ann. Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib215","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.1128\/JVI.00351-16","article-title":"Intracellular distribution of capsid-associated pUL77 of human cytomegalovirus and interactions with packaging proteins and pUL93","volume":"90","author":"Koppen-Rung","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib216","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1128\/AAC.46.8.2373-2380.2002","article-title":"Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication","volume":"46","author":"Koszalka","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib217","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/TP.0b013e3181cee42f","article-title":"International consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"89","author":"Kotton","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2018.09.003_bib218","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003333","article-title":"Saturated very long chain fatty acids are required for the production of infectious human cytomegalovirus progeny","volume":"9","author":"Koyuncu","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.09.003_bib219","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002203","article-title":"Zika Virus Infection as a Cause of Congenital Brain Abnormalities and Guillain-Barre Syndrome: systematic Review","volume":"14","author":"Krauer","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib220","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jcv.2018.01.002","article-title":"Assessing the risk of CMV reactivation and reconstitution of antiviral immune response post bone marrow transplantation by the QuantiFERON-CMV-assay and real time PCR","volume":"99\u2013100","author":"Krawczyk","year":"2018","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib221","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01754-17","article-title":"Latency-associated expression of human cytomegalovirus US28 attenuates cell signaling pathways to maintain latent infection","volume":"8","author":"Krishna","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2018.09.003_bib222","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/bcp.13292","article-title":"Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment","volume":"83","author":"Kropeit","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.antiviral.2018.09.003_bib223","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/cpdd.388","article-title":"Pharmacokinetics and safety of letermovir coadministered with cyclosporine a or tacrolimus in healthy subjects","volume":"7","author":"Kropeit","year":"2018","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.antiviral.2018.09.003_bib224","doi-asserted-by":"crossref","first-page":"7720","DOI":"10.1128\/JVI.77.14.7720-7727.2003","article-title":"The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase","volume":"77","author":"Krosky","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib225","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1128\/AAC.46.2.478-486.2002","article-title":"Phosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirus","volume":"46","author":"Krosky","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib226","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/JVI.72.6.4721-4728.1998","article-title":"Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56","volume":"72","author":"Krosky","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib227","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/ajt.14347","article-title":"An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation","volume":"17","author":"Kumar","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib228","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1007\/s12325-017-0642-4","article-title":"Pharmacokinetics and safety of amenamevir in healthy subjects: analysis of four randomized phase 1 studies","volume":"34","author":"Kusawake","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.antiviral.2018.09.003_bib229","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1081\/NCN-120026633","article-title":"Efficacy of methylenecyclopropane analogs of nucleosides against herpesvirus replication in vitro","volume":"22","author":"Kushner","year":"2003","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.09.003_bib230","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.transproceed.2011.12.025","article-title":"Post-renal transplant cytomegalovirus infection: study of risk factors","volume":"44","author":"Kute","year":"2012","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.antiviral.2018.09.003_bib231","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bbmt.2003.12.004","article-title":"Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants","volume":"10","author":"Lacey","year":"2004","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib232","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1128\/AAC.46.9.2969-2976.2002","article-title":"Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding","volume":"46","author":"Lalezari","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib233","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-126-4-199702150-00001","article-title":"Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial","volume":"126","author":"Lalezari","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib234","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004881","article-title":"Human Cytomegalovirus miR-UL112-3p Targets TLR2 and Modulates the TLR2\/IRAK1\/NFkappaB Signaling Pathway","volume":"11","author":"Landais","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.09.003_bib235","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/infdis\/jiw073","article-title":"Analysis of mutations in the gene encoding cytomegalovirus DNA polymerase in a phase 2 clinical trial of brincidofovir prophylaxis","volume":"214","author":"Lanier","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib236","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2610","article-title":"Hearing loss in children with asymptomatic congenital cytomegalovirus infection","volume":"139","author":"Lanzieri","year":"2017","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.antiviral.2018.09.003_bib237","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/jp.2017.41","article-title":"Long-term outcomes of children with symptomatic congenital cytomegalovirus disease","volume":"37","author":"Lanzieri","year":"2017","journal-title":"J. Perinatol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib238","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jcv.2015.08.009","article-title":"Prospective long-term study on primary CMV infections in adult liver transplant (D+\/R-) patients after valganciclovir prophylaxis","volume":"71","author":"Lautenschlager","year":"2015","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib239","doi-asserted-by":"crossref","first-page":"28059","DOI":"10.1074\/jbc.274.40.28059","article-title":"Replication of herpes simplex virus DNA","volume":"274","author":"Lehman","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.09.003_bib240","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1084\/jem.20151899","article-title":"Inflammatory monocytes and NK cells play a crucial role in DNAM-1-dependent control of cytomegalovirus infection","volume":"213","author":"Lenac Rovis","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib241","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2165\/00003495-200060060-00007","article-title":"Current recommendations for the treatment of genital herpes","volume":"60","author":"Leung","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2018.09.003_bib242","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.chom.2013.10.007","article-title":"Human cytomegalovirus tegument protein pUL83 inhibits IFI16-mediated DNA sensing for immune evasion","volume":"14","author":"Li","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2018.09.003_bib243","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/femsre\/fuy004","article-title":"The human cytomegalovirus terminase complex as an antiviral target: a close-up view","volume":"42","author":"Ligat","year":"2018","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2018.09.003_bib244","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/01.TP.0000145989.22373.03","article-title":"Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis","volume":"78","author":"Limaye","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2018.09.003_bib245","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/j.transproceed.2011.05.007","article-title":"Influence of cytomegalovirus disease in outcome of solid organ transplant patients","volume":"43","author":"Linares","year":"2011","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.antiviral.2018.09.003_bib246","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib247","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiv352","article-title":"Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228)","volume":"213","author":"Lischka","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib248","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/358160a0","article-title":"Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir","volume":"358","author":"Littler","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.09.003_bib249","series-title":"Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis","article-title":"Comparative virion structures of human herpesviruses","author":"Liu","year":"2007"},{"key":"10.1016\/j.antiviral.2018.09.003_bib250","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib251","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1016\/j.transproceed.2010.07.101","article-title":"Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation","volume":"42","author":"Lochmanova","year":"2010","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.antiviral.2018.09.003_bib252","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.105.009209","article-title":"N-methylpurine DNA glycosylase and 8-oxoguanine dna glycosylase metabolize the antiviral nucleoside 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole","volume":"34","author":"Lorenzi","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.antiviral.2018.09.003_bib253","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ajt.13529","article-title":"Late failing heart allografts: pathology of cardiac allograft vasculopathy and association with antibody-mediated rejection","volume":"16","author":"Loupy","year":"2016","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib254","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1056\/NEJM199905133401903","article-title":"Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International valacyclovir cytomegalovirus prophylaxis transplantation study group","volume":"340","author":"Lowance","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib255","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.healun.2011.04.008","article-title":"Diverse morphologic manifestations of cardiac allograft vasculopathy: a pathologic study of 64 allograft hearts","volume":"30","author":"Lu","year":"2011","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib256","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1399-3062.2010.00532.x","article-title":"Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients","volume":"12","author":"Luan","year":"2010","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib257","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/cid\/ciu589","article-title":"Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients","volume":"59","author":"Lucia","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib258","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2018.09.003_bib259","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1128\/AAC.50.4.1130-1135.2006","article-title":"Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults","volume":"50","author":"Ma","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib260","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/j.1600-6143.2008.02299.x","article-title":"A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation","volume":"8","author":"Magliocca","year":"2008","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib261","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1007\/s00247-011-2120-5","article-title":"Brain magnetic resonance findings in symptomatic congenital cytomegalovirus infection","volume":"41","author":"Manara","year":"2011","journal-title":"Pediatr. Radiol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib262","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/CMR.00062-12","article-title":"The \u201csilent\u201d global burden of congenital cytomegalovirus","volume":"26","author":"Manicklal","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2018.09.003_bib263","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/cid\/ciu096","article-title":"Birth prevalence of congenital cytomegalovirus among infants of HIV-infected women on prenatal antiretroviral prophylaxis in South Africa","volume":"58","author":"Manicklal","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib264","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/cis993","article-title":"Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study","volume":"56","author":"Manuel","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib265","doi-asserted-by":"crossref","first-page":"10658","DOI":"10.3748\/wjg.v20.i31.10658","article-title":"Cytomegalovirus infection in liver transplant recipients: updates on clinical management","volume":"20","author":"Marcelin","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib266","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/bmt.2013.132","article-title":"The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT","volume":"49","author":"Marek","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib267","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0042-6822(03)00147-8","article-title":"The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44","volume":"311","author":"Marschall","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.09.003_bib268","doi-asserted-by":"crossref","first-page":"33357","DOI":"10.1074\/jbc.M502672200","article-title":"Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina","volume":"280","author":"Marschall","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.09.003_bib269","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1128\/AAC.05908-11","article-title":"In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses","volume":"56","author":"Marschall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib270","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1099\/0022-1317-82-6-1439","article-title":"Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97","volume":"82","author":"Marschall","year":"2001","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib271","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1099\/0022-1317-83-5-1013","article-title":"Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy","volume":"83","author":"Marschall","year":"2002","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib272","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1111\/ajt.13486","article-title":"The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation","volume":"15","author":"Martin-Gandul","year":"2015","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib273","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/tri.12378","article-title":"Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy","volume":"27","author":"Martin-Gandul","year":"2014","journal-title":"Transpl. Int."},{"issue":"25","key":"10.1016\/j.antiviral.2018.09.003_bib274","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib275","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib276","first-page":"S52","article-title":"Brincidofovir for prevention of cytomegalovirus (CMV) after allogeneic hematopoietic cell transplantation (HCT) in CMV-seropositive patients: a randomized, double-blind, placebo-controlled, parallel-group phase 3 trial","author":"Marty","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib277","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib278","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1086\/383040","article-title":"A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients","volume":"189","author":"Mattes","year":"2004","journal-title":"J. Infect. Dis."},{"issue":"Suppl. 3","key":"10.1016\/j.antiviral.2018.09.003_bib279","doi-asserted-by":"crossref","first-page":"S490","DOI":"10.1093\/clinids\/10.Supplement_3.S490","article-title":"Antiviral activity and mechanism of action of ganciclovir","volume":"10","author":"Matthews","year":"1988","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002502","article-title":"HCMV targets the metabolic stress response through activation of AMPK whose activity is important for viral replication","volume":"8","author":"McArdle","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.09.003_bib281","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.virusres.2006.01.002","article-title":"Topics in herpesvirus genomics and evolution","volume":"117","author":"McGeoch","year":"2006","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib282","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1128\/AAC.45.10.2925-2927.2001","article-title":"Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir","volume":"45","author":"McSharry","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib283","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1128\/CDLI.8.6.1279-1281.2001","article-title":"Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94","volume":"8","author":"McSharry","year":"2001","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib284","doi-asserted-by":"crossref","first-page":"11115","DOI":"10.1128\/JVI.79.17.11115-11127.2005","article-title":"Impact of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside and inhibitors of DNA, RNA, and protein synthesis on human cytomegalovirus genome maturation","volume":"79","author":"McVoy","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib285","first-page":"269","article-title":"Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus","volume":"8","author":"Melendez","year":"2015","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.antiviral.2018.09.003_bib286","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.transproceed.2012.09.035","article-title":"Cumulative incidence of cytomegalovirus infection and disease after heart transplantation in the last decade: effect of preemptive therapy","volume":"44","author":"Mendez-Eirin","year":"2012","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.antiviral.2018.09.003_bib287","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/rmv.558","article-title":"Human cytomegalovirus DNA replication: antiviral targets and drugs","volume":"18","author":"Mercorelli","year":"2008","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib288","series-title":"Cytomegaloviruses: from Molecular Pathogenesis to Intervention","first-page":"402","article-title":"Antiviral therapy, drug resistance and computed resistance profiling","author":"Michel","year":"2013"},{"key":"10.1016\/j.antiviral.2018.09.003_bib289","doi-asserted-by":"crossref","first-page":"13979","DOI":"10.1074\/jbc.M109.063628","article-title":"Novel mode of phosphorylation-triggered reorganization of the nuclear lamina during nuclear egress of human cytomegalovirus","volume":"285","author":"Milbradt","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.09.003_bib290","first-page":"1180","article-title":"Etiology of cytomegaly in infants","volume":"83","author":"Minder","year":"1953","journal-title":"Schweiz. Med. Wochenschr."},{"key":"10.1016\/j.antiviral.2018.09.003_bib291","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMra050700","article-title":"Newborn hearing screening--a silent revolution","volume":"354","author":"Morton","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib292","first-page":"98","article-title":"Infectious complications in cord blood and T-cell depleted haploidentical stem cell transplantation","volume":"1","author":"Mulanovich","year":"2011","journal-title":"Am. J. Blood Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib293","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/nbt.1500","article-title":"Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy","volume":"26","author":"Munger","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib294","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1086\/600882","article-title":"Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population","volume":"49","author":"Mussi-Pinhata","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib295","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/cid\/cit766","article-title":"High rates of congenital cytomegalovirus infection linked with maternal HIV infection among neonatal admissions at a large referral center in sub-Saharan Africa","volume":"58","author":"Mwaanza","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib296","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7326\/0003-4819-82-2-181","article-title":"Cytomegalovirus pneumonia after human marrow transplantation","volume":"82","author":"Myers","year":"1975","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib297","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1086\/340101","article-title":"Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients","volume":"34","author":"Mylonakis","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib298","doi-asserted-by":"crossref","first-page":"ofw107","DOI":"10.1093\/ofid\/ofw107","article-title":"Efficacy and safety of a preemptive antiviral therapy strategy based on combined virological and immunological monitoring for active cytomegalovirus infection in allogeneic stem cell transplant recipients","volume":"3","author":"Navarro","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib299","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/infdis\/jiw064","article-title":"Utility of the enzyme-linked immunospot interferon-gamma-release assay to predict the risk of cytomegalovirus infection in hematopoietic cell transplant recipients","volume":"213","author":"Nesher","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib300","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02384-16","article-title":"Mutual interplay between the human cytomegalovirus terminase subunits pUL51, pUL56, and pUL89 promotes terminase complex formation","volume":"91","author":"Neuber","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib301","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1681\/ASN.2008101037","article-title":"Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients","volume":"20","author":"Noel","year":"2009","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"10.1016\/j.antiviral.2018.09.003_bib302","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1128\/AAC.46.3.724-730.2002","article-title":"Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors","volume":"46","author":"Oien","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib303","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/INF.0000000000000555","article-title":"Prevalence of congenital cytomegalovirus infection in Nigeria: a pilot study","volume":"34","author":"Olusanya","year":"2015","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.antiviral.2018.09.003_bib304","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/tri.12101","article-title":"Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients","volume":"26","author":"Onor","year":"2013","journal-title":"Transpl. Int."},{"key":"10.1016\/j.antiviral.2018.09.003_bib305","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.05983-11","article-title":"First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses","volume":"56","author":"Painter","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib306","first-page":"153","article-title":"Nuts and bolts of human cytomegalovirus lytic DNA replication","volume":"325","author":"Pari","year":"2008","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib307","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1074-7613(03)00355-8","article-title":"Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion","volume":"20","author":"Park","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.antiviral.2018.09.003_bib308","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jcv.2005.09.015","article-title":"Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome","volume":"35","author":"Pass","year":"2006","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib309","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1542\/peds.66.5.758","article-title":"Outcome of symptomatic congenital CMV infection: results of long-term longitudinal follow-up","volume":"66","author":"Pass","year":"1980","journal-title":"Pediatrics"},{"key":"10.1016\/j.antiviral.2018.09.003_bib310","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3390\/v1030760","article-title":"The human cytomegalovirus major immediate-early proteins as antagonists of intrinsic and innate antiviral host responses","volume":"1","author":"Paulus","year":"2009","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2018.09.003_bib311","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/00003088-200948060-00006","article-title":"Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements","volume":"48","author":"Perrottet","year":"2009","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.antiviral.2018.09.003_bib312","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/QCO.0000000000000288","article-title":"Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management","volume":"29","author":"Piret","year":"2016","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.antiviral.2018.09.003_bib313","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01044-17","article-title":"Drug susceptibility and replicative capacity of multidrug-resistant recombinant human cytomegalovirus harboring mutations in UL56 and UL54 genes","volume":"61","author":"Piret","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib314","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00430-015-0401-6","article-title":"Sleepless latency of human cytomegalovirus","volume":"204","author":"Poole","year":"2015","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib315","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/01.tp.0000229039.87735.76","article-title":"Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection","volume":"82","author":"Potena","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2018.09.003_bib316","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/QCO.0b013e328259c33b","article-title":"Cytomegalovirus-associated allograft rejection in heart transplant patients","volume":"20","author":"Potena","year":"2007","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib317","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/rmv.615","article-title":"Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir","volume":"19","author":"Prichard","year":"2009","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib318","doi-asserted-by":"crossref","first-page":"15494","DOI":"10.1128\/JVI.79.24.15494-15502.2005","article-title":"Human cytomegalovirus UL97 Kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis","volume":"79","author":"Prichard","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib319","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/jvi.70.5.3018-3025.1996","article-title":"Human cytomegalovirus uracil DNA glycosylase is required for the normal temporal regulation of both DNA synthesis and viral replication","volume":"70","author":"Prichard","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib320","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1128\/JVI.73.7.5663-5670.1999","article-title":"A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency","volume":"73","author":"Prichard","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib321","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.virusres.2010.11.004","article-title":"The search for new therapies for human cytomegalovirus infections","volume":"157","author":"Prichard","year":"2011","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib322","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1743-422X-2-55","article-title":"Human cytomegalovirus uracil DNA glycosylase associates with ppUL44 and accelerates the accumulation of viral DNA","volume":"2","author":"Prichard","year":"2005","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2018.09.003_bib323","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1743-422X-3-18","article-title":"Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID mice","volume":"3","author":"Prichard","year":"2006","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2018.09.003_bib324","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1128\/JVI.02174-07","article-title":"Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes","volume":"82","author":"Prichard","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib325","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1128\/AAC.00429-13","article-title":"Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses","volume":"57","author":"Prichard","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib326","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.4049\/jimmunol.1102068","article-title":"Human cytomegalovirus UL40 signal peptide regulates cell surface expression of the NK cell ligands HLA-E and gpUL18","volume":"188","author":"Prod'homme","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib327","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/QCO.0b013e32821f6026","article-title":"Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: current approach and future challenges","volume":"20","author":"Puius","year":"2007","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib328","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.celrep.2015.02.003","article-title":"Fatty acid elongase 7 catalyzes lipidome remodeling essential for human cytomegalovirus replication","volume":"10","author":"Purdy","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.antiviral.2018.09.003_bib329","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/095632020001100302","article-title":"Synthesis and enantioselectivity of the antiviral effects of (R,Z)-,(S,Z)-methylenecyclopropane analogues of purine nucleosides and phosphoralaninate prodrugs: influence of heterocyclic base, type of virus and host cells","volume":"11","author":"Qiu","year":"2000","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib330","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/jm9705723","article-title":"(Z)- and (E)-2-((hydroxymethyl)cyclopropylidene)methyladenine and -guanine. New nucleoside analogues with a broad-spectrum antiviral activity","volume":"41","author":"Qiu","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.09.003_bib331","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0166-3542(99)00029-7","article-title":"Synthesis and antiviral activity of phosphoralaninate derivatives of methylenecyclopropane analogues of nucleosides","volume":"43","author":"Qiu","year":"1999","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib332","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/095632029800900406","article-title":"(Z)- and (E)-2-(hydroxymethylcyclopropylidene)-methylpurines and pyrimidines as antiviral agents","volume":"9","author":"Qiu","year":"1998","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib333","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1128\/AAC.48.2.404-412.2004","article-title":"Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir","volume":"48","author":"Quenelle","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib334","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1161\/01.RES.0000246086.93555.f3","article-title":"Allograft vasculopathy versus atherosclerosis","volume":"99","author":"Rahmani","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib335","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/bmt.2016.89","article-title":"Impact of early CMV reactivation in cord blood stem cell recipients in the current era","volume":"51","author":"Ramanathan","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib336","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1128\/AAC.50.4.1564-1566.2006","article-title":"Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro","volume":"50","author":"Randhawa","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib337","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jmb.2008.05.028","article-title":"Characterization of human cytomegalovirus uracil DNA glycosylase (UL114) and its interaction with polymerase processivity factor (UL44)","volume":"381","author":"Ranneberg-Nilsen","year":"2008","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib338","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1073\/pnas.81.3.876","article-title":"Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus","volume":"81","author":"Rasmussen","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.09.003_bib339","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/tid.12447","article-title":"It's not too late: a proposal to standardize the terminology of \u201clate-onset\u201d cytomegalovirus infection and disease in solid organ transplant recipients","volume":"17","author":"Razonable","year":"2015","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib340","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1086\/324516","article-title":"Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir","volume":"184","author":"Razonable","year":"2001","journal-title":"JID (J. Infect. Dis.)"},{"key":"10.1016\/j.antiviral.2018.09.003_bib341","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01554-16","article-title":"Phosphorylation of golgi peripheral membrane protein Grasp65 is an integral step in the formation of the human cytomegalovirus cytoplasmic assembly compartment","volume":"7","author":"Rebmann","year":"2016","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2018.09.003_bib342","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jac\/48.6.757","article-title":"Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action","volume":"48","author":"Reefschlaeger","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib343","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3390\/v5061395","article-title":"Regulation of human cytomegalovirus transcription in latency: beyond the major immediate-early promoter","volume":"5","author":"Reeves","year":"2013","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2018.09.003_bib344","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/TP.0b013e318192ded5","article-title":"Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis","volume":"87","author":"Reischig","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2018.09.003_bib345","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jcv.2006.01.015","article-title":"The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection","volume":"36","author":"Reischig","year":"2006","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib346","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3851\/IMP3129","article-title":"The impact of viral load and time to onset of cytomegalovirus replication on long-term graft survival after kidney transplantation","volume":"22","author":"Reischig","year":"2017","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2018.09.003_bib347","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.chom.2011.01.006","article-title":"Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest","volume":"9","author":"Reitsma","year":"2011","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2018.09.003_bib348","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001344","article-title":"Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants","volume":"7","author":"Renzette","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.09.003_bib349","doi-asserted-by":"crossref","first-page":"E4120","DOI":"10.1073\/pnas.1501880112","article-title":"Limits and patterns of cytomegalovirus genomic diversity in humans","volume":"112","author":"Renzette","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.09.003_bib350","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJMoa1310214","article-title":"A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus","volume":"370","author":"Revello","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib351","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.trre.2014.01.001","article-title":"The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients","volume":"28","author":"Roman","year":"2014","journal-title":"Transplant. Rev."},{"key":"10.1016\/j.antiviral.2018.09.003_bib352","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1086\/649903","article-title":"Cytomegalovirus reinfections in healthy seroimmune women","volume":"201","author":"Ross","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib353","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/infdis\/jir457","article-title":"Mixed infection and strain diversity in congenital cytomegalovirus infection","volume":"204","author":"Ross","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib354","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1128\/AAC.44.6.1506-1511.2000","article-title":"In vitro activities of methylenecyclopropane analogues of nucleosides and their phosphoralaninate prodrugs against cytomegalovirus and other herpesvirus infections","volume":"44","author":"Rybak","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib355","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0166-3542(99)00043-1","article-title":"Effective treatment of murine cytomegalovirus infections with methylenecyclopropane analogues of nucleosides","volume":"43","author":"Rybak","year":"1999","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib356","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1128\/JVI.80.8.3863-3871.2006","article-title":"Inactivating a cellular intrinsic immune defense mediated by Daxx is the mechanism through which the human cytomegalovirus pp71 protein stimulates viral immediate-early gene expression","volume":"80","author":"Saffert","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib357","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/(SICI)1099-1654(199709)7:3<145::AID-RMV196>3.0.CO;2-0","article-title":"Clinical uses of cidofovir","volume":"7","author":"Safrin","year":"1997","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib358","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-4615-4743-3_10","article-title":"Cidofovir. Review of current and potential clinical uses","volume":"458","author":"Safrin","year":"1999","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib359","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1128\/JVI.72.4.3321-3329.1998","article-title":"Localization of human cytomegalovirus structural proteins to the nuclear matrix of infected human fibroblasts","volume":"72","author":"Sanchez","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib360","first-page":"243","article-title":"Subversion of cell cycle regulatory pathways","volume":"325","author":"Sanchez","year":"2008","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib361","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1097\/TP.0000000000000549","article-title":"Incidence, risk factors and outcomes of delayed-onset cytomegalovirus disease in a large retrospective cohort of lung transplant recipients","volume":"99","author":"Santos","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2018.09.003_bib362","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10096-016-2605-0","article-title":"Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections","volume":"35","author":"Sauerbrei","year":"2016","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib363","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1097\/TP.0000000000001825","article-title":"CMV-specific T cell monitoring offers superior risk stratification of CMV-seronegative kidney transplant recipients of a CMV-seropositive donor","volume":"101","author":"Schachtner","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2018.09.003_bib364","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/nar\/30.7.1695","article-title":"The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure","volume":"30","author":"Scheffczik","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib365","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1128\/JVI.01973-15","article-title":"Characterization of recombinant human cytomegaloviruses encoding IE1 mutants L174P and 1-382 reveals that viral targeting of PML bodies perturbs both intrinsic and innate immune responses","volume":"90","author":"Scherer","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib366","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1128\/JVI.01979-15","article-title":"Emerging role of PML nuclear bodies in innate immune signaling","volume":"90","author":"Scherer","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib367","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/infdis\/172.2.531","article-title":"Mouse cytomegalovirus reactivation in severe combined immune deficient mice after implantation of latently infected salivary gland","volume":"172","author":"Schmader","year":"1995","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib368","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1600-6143.2012.04339.x","article-title":"Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV serostatus guide the duration of prophylaxis?","volume":"13","author":"Schoeppler","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib369","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev-virology-031413-085425","article-title":"Human cytomegalovirus: coordinating cellular stress, signaling, and metabolic pathways","volume":"1","author":"Shenk","year":"2014","journal-title":"Ann. Rev. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib370","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1358\/dot.2017.53.11.2724803","article-title":"Helicase-primase inhibitor amenamevir for herpesvirus infection: towards practical application for treating herpes zoster","volume":"53","author":"Shiraki","year":"2017","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.antiviral.2018.09.003_bib371","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12629","article-title":"Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation","volume":"19","author":"Slade","year":"2017","journal-title":"Transpl. Infect. Dis."},{"issue":"3","key":"10.1016\/j.antiviral.2018.09.003_bib372","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.chom.2010.08.001","article-title":"Granulocyte-colony stimulating factor reactivates human cytomegalovirus in a latently infected humanized mouse model","volume":"8","author":"Smith","year":"2010","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2018.09.003_bib373","first-page":"1561","article-title":"Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients","volume":"3","author":"Snoeck","year":"2002","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.antiviral.2018.09.003_bib374","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1128\/AAC.32.12.1839","article-title":"(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication","volume":"32","author":"Snoeck","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib375","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0041-1345(03)00715-2","article-title":"Significance of cytomegalovirus infection in renal transplantation","volume":"35","author":"Sola","year":"2003","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.antiviral.2018.09.003_bib376","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00430-015-0396-z","article-title":"Human cytomegalovirus riding the cell cycle","volume":"204","author":"Spector","year":"2015","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib377","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1001\/jama.1986.03380140074025","article-title":"Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome","volume":"256","author":"Stagno","year":"1986","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.antiviral.2018.09.003_bib378","first-page":"31","article-title":"Congenital and perinatal cytomegalovirus infections","volume":"7","author":"Stagno","year":"1983","journal-title":"Semin. Perinatol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib379","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1542\/peds.59.5.669","article-title":"Auditory and visual defects resulting from symptomatic and subclinical congenital cytomegaloviral and toxoplasma infections","volume":"59","author":"Stagno","year":"1977","journal-title":"Pediatrics"},{"key":"10.1016\/j.antiviral.2018.09.003_bib380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003544","article-title":"Cytomegalovirus downregulates IRE1 to repress the unfolded protein response","volume":"9","author":"Stahl","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.09.003_bib381","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0887-8994(96)00170-1","article-title":"Late intrauterine Cytomegalovirus infection: clinical and neuroimaging findings","volume":"15","author":"Steinlin","year":"1996","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib382","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1126\/science.1227919","article-title":"Decoding human cytomegalovirus","volume":"338","author":"Stern-Ginossar","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2018.09.003_bib383","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/TP.0000000000000160","article-title":"Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment","volume":"98","author":"Stern","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2018.09.003_bib384","series-title":"The Herpesviruses","first-page":"67","article-title":"Molecular biology of cytomegaloviruses","author":"Stinski","year":"1983"},{"key":"10.1016\/j.antiviral.2018.09.003_bib385","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1099\/vir.0.022160-0","article-title":"Interaction of the human cytomegalovirus uracil DNA glycosylase UL114 with the viral DNA polymerase catalytic subunit UL54","volume":"91","author":"Strang","year":"2010","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib386","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.coi.2007.07.012","article-title":"Acceleration of allograft failure by cytomegalovirus","volume":"19","author":"Streblow","year":"2007","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib387","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005868","article-title":"Natural Killer Cell Evasion Is Essential for Infection by Rhesus Cytomegalovirus","volume":"12","author":"Sturgill","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.09.003_bib388","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00588225","article-title":"Magnetic resonance imaging of the brain in congenital rubella virus and cytomegalovirus infections","volume":"33","author":"Sugita","year":"1991","journal-title":"Neuroradiology"},{"key":"10.1016\/j.antiviral.2018.09.003_bib389","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/359085a0","article-title":"A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells","volume":"359","author":"Sullivan","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.09.003_bib390","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1084\/jem.20050882","article-title":"Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects","volume":"202","author":"Sylwester","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib391","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.bbmt.2015.07.019","volume":"21","author":"Takenaka","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib392","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1128\/AAC.43.8.1941","article-title":"Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein","volume":"43","author":"Talarico","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib393","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2018.09.003_bib394","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074744","article-title":"Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV(R) assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications","volume":"8","author":"Tey","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.09.003_bib395","doi-asserted-by":"crossref","first-page":"8855","DOI":"10.1021\/bi0600796","article-title":"Identification of the interaction domain of the small terminase subunit pUL89 with the large subunit pUL56 of human cytomegalovirus","volume":"45","author":"Thoma","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2018.09.003_bib396","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1399-0012.2009.00990.x","article-title":"Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen","volume":"23","author":"Thomas","year":"2009","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.antiviral.2018.09.003_bib397","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/S0140-6736(16)32187-0","article-title":"Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial","volume":"388","author":"Thomusch","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2018.09.003_bib398","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/FTD.0000000000000353","article-title":"Brincidofovir is not a substrate for the human organic anion transporter 1: a mechanistic explanation for the lack of nephrotoxicity observed in clinical studies","volume":"38","author":"Tippin","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.antiviral.2018.09.003_bib399","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/590934","article-title":"Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients","volume":"47","author":"Torres-Madriz","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib400","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1021\/jm00020a025","article-title":"Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D-ribofuranosyl)benzimidazoles","volume":"38","author":"Townsend","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.09.003_bib401","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0885066613476454","article-title":"Cytomegalovirus pneumonia in hematopoietic stem cell recipients","volume":"29","author":"Travi","year":"2014","journal-title":"J. Intensive Care Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib402","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00262-009-0722-7","article-title":"The prevention and treatment of cytomegalovirus infection in haematopoietic stem cell transplantation","volume":"58","author":"Tuthill","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib403","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1128\/AAC.48.5.1647-1651.2004","article-title":"Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus","volume":"48","author":"Underwood","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib404","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1128\/JVI.72.1.717-725.1998","article-title":"Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product","volume":"72","author":"Underwood","year":"1998","journal-title":"J. Virol."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2018.09.003_bib405","first-page":"25","article-title":"Role of CMV in transplant coronary artery disease and survival after heart transplantation","volume":"1","author":"Valantine","year":"1999","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib406","first-page":"Cr609","article-title":"Latent cytomegalovirus infection is an independent risk factor for late graft failure in renal transplant recipients","volume":"17","author":"van Ree","year":"2011","journal-title":"Med. Sci. Mon. Int. Med. J. Exp. Clin. Res. Int. Med. J. Exp. Clin. Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib407","doi-asserted-by":"crossref","first-page":"11965","DOI":"10.1128\/JVI.01718-15","article-title":"Deficiencies in cellular processes modulated by the retinoblastoma protein do not account for reduced human cytomegalovirus replication in its absence","volume":"89","author":"VanDeusen","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib408","doi-asserted-by":"crossref","first-page":"10960","DOI":"10.1128\/JVI.78.20.10960-10966.2004","article-title":"Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome","volume":"78","author":"Varnum","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib409","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/tid.12408","article-title":"Two-year post-transplantation cytomegalovirus DNAemia in asymptomatic kidney transplant recipients: incidence, risk factors, and outcome","volume":"17","author":"Viot","year":"2015","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib410","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1056\/NEJMoa1301150","article-title":"Helicase-primase inhibitor pritelivir for HSV-2 infection","volume":"370","author":"Wald","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.09.003_bib411","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/jama.2016.18189","article-title":"Effect of pritelivir compared with valacyclovir on genital HSV-2 shedding in patients with frequent recurrences: a randomized clinical trial","volume":"316","author":"Wald","year":"2016","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.antiviral.2018.09.003_bib412","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/infdis\/157.3.569","article-title":"Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet)","volume":"157","author":"Walmsley","year":"1988","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib413","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1128\/AAC.49.2.656-662.2005","article-title":"Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro","volume":"49","author":"Wan","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib414","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2018.01.015","article-title":"Metal-chelating 3-hydroxypyrimidine-2,4-diones inhibit human cytomegalovirus pUL89 endonuclease activity and virus replication","volume":"152","author":"Wang","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib415","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/rmv.354","article-title":"Non-nucleoside inhibitors of herpesviruses","volume":"12","author":"Wathen","year":"2002","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib416","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1128\/JVI.00192-14","article-title":"Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility","volume":"88","author":"Webel","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib417","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.cell.2014.04.028","article-title":"Quantitative temporal viromics: an approach to investigate host-pathogen interaction","volume":"157","author":"Weekes","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2018.09.003_bib418","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006193","article-title":"Synthetic lethal mutations in the cyclin A interface of human cytomegalovirus","volume":"13","author":"Weisbach","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.09.003_bib419","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1097\/TP.0000000000000687","article-title":"Evaluation of alemtuzumab versus basiliximab induction: a retrospective cohort study in lung transplant recipients","volume":"99","author":"Whited","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2018.09.003_bib420","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1128\/AAC.49.9.3724-3733.2005","article-title":"Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro","volume":"49","author":"Williams-Aziz","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib421","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1128\/AAC.47.7.2186-2192.2003","article-title":"In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses","volume":"47","author":"Williams","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib422","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/TP.0b013e318238dab3","article-title":"Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial","volume":"93","author":"Witzke","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2018.09.003_bib423","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1073\/pnas.98.4.1895","article-title":"Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation","volume":"98","author":"Wolf","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.09.003_bib424","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1432-2277.1999.tb01210.x","article-title":"Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients","volume":"12","author":"Wreghitt","year":"1999","journal-title":"Transpl. Int."},{"key":"10.1016\/j.antiviral.2018.09.003_bib425","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.4049\/jimmunol.170.8.4196","article-title":"Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein","volume":"170","author":"Wu","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib426","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3851\/IMP782","article-title":"L-valine ester of cyclopropavir: a new antiviral prodrug","volume":"20","author":"Wu","year":"2009","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib427","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-3476(50)80097-5","article-title":"Generalized cytomegalic inclusion disease","volume":"36","author":"Wyatt","year":"1950","journal-title":"J. Pediatr."},{"key":"10.1016\/j.antiviral.2018.09.003_bib428","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1128\/AAC.41.3.594","article-title":"Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation","volume":"41","author":"Xiong","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.09.003_bib429","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/0006-2952(96)00100-1","article-title":"Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase","volume":"51","author":"Xiong","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib430","doi-asserted-by":"crossref","first-page":"10360","DOI":"10.1128\/JVI.78.19.10360-10369.2004","article-title":"Human cytomegalovirus UL84 insertion mutant defective for viral DNA synthesis and growth","volume":"78","author":"Xu","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib431","series-title":"The Contribution of Congenital CMV Infection to Hearing Loss in Childhood: Can it Be Evaluated without Systematic CMV Neonatal Screening? Manuscript in Prepartion","author":"Yamamoto","year":"2018"},{"key":"10.1016\/j.antiviral.2018.09.003_bib432","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2009.11.018","article-title":"Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population","volume":"202","author":"Yamamoto","year":"2010","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib433","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/INF.0b013e31822d9640","article-title":"Congenital cytomegalovirus infection as a cause of sensorineural hearing loss in a highly immune population","volume":"30","author":"Yamamoto","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.antiviral.2018.09.003_bib434","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/infdis\/jix192","article-title":"Identifying cytomegalovirus complications using the quantiferon-CMV assay after allogeneic hematopoietic stem cell transplantation","volume":"215","author":"Yong","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib435","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.tim.2011.04.002","article-title":"Viral effects on metabolism: changes in glucose and glutamine utilization during human cytomegalovirus infection","volume":"19","author":"Yu","year":"2011","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.antiviral.2018.09.003_bib436","series-title":"Allenols Derived from Nucleic Acids Bases \u2013 a New Class of Anti-hiv Agents: Chemistry and Biological Activity","author":"Zemlicka","year":"1993"},{"key":"10.1016\/j.antiviral.2018.09.003_bib437","series-title":"Unusual Analogues of Nucleosides: Chemistry and Biological Activity","author":"Zemlicka","year":"2002"},{"key":"10.1016\/j.antiviral.2018.09.003_bib438","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1399-3062.2011.00652.x","article-title":"Preemptive versus prophylactic protocol to prevent cytomegalovirus infection after renal transplantation: a meta-analysis and systematic review of randomized controlled trials","volume":"13","author":"Zhang","year":"2011","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.09.003_bib439","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1021\/jm030316s","article-title":"Synthesis and antiviral activity of (Z)- and (E)-2,2-[bis(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines: second-generation methylenecyclopropane analogues of nucleosides","volume":"47","author":"Zhou","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.09.003_bib440","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0166-3542(97)00034-X","article-title":"Phosphorylation of aciclovir, ganciclovir, penciclovir and S2242 by the cytomegalovirus UL97 protein: a quantitative analysis using recombinant vaccinia viruses","volume":"36","author":"Zimmermann","year":"1997","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib441","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0166-3542(00)00118-2","article-title":"Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase","volume":"48","author":"Zimmermann","year":"2000","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.09.003_bib442","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1099\/jgv.0.000872","article-title":"Assemblins as maturational proteases in herpesviruses","volume":"98","author":"Zuhlsdorf","year":"2017","journal-title":"J. Gen. Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218304315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218304315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:28:41Z","timestamp":1759062521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218304315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":442,"alternative-id":["S0166354218304315"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.09.003","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New therapies for human cytomegalovirus infections","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}